This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

1.

Anwar R and Miloszewski KJ. Br J Haematol. 1999;107(3):468-484.

2.

Williams M, Will A, Stenmo C et al. Haemophilia. 2014;20(1):99-105.

3.

Sharief LAT and Kadir RA. Haemophilia. 2013;19(6):e349-e357.

4.

Hsieh Land Nugent D. Haemophilia. 2008;14(6):1190-1200.

5.

Odame JE, Chan AK, Wu JK et al. Blood Coagul Fibrinolysis. 2014;25(3):199-205.

6.

Bolton-Maggs PHB. Treatment of Hemophilia. April 2006. No 39. World Federation of Hemophilia.

7.

Carcao M, Altisent C, Castaman G et al. Thromb Haemost. 2018;118(3):451-460.

8.

Carcao M, Fukutake K, Inbal A et al. Semin Thromb Hemost. 2017;43(1):59-68.

9.

Dorey E. Nat Biotechnol. 2014;32:210.

10.

NovoThirteen® Summary of Product Characteristics.

11.

Inbal A, Oldenburg J, Carcao M et al. Blood. 2012;119(22):5111-5117.

12.

Kerlin BA, Inbal A, Will A et al. J Thromb Haemost. 2017;15(8):1601-1606.

13.

Hvitfeldt Poulsen L, Kerlin BA, Castaman G et al. Res Pract Thromb Haemost. 2020;4(Suppl 1 ). Abstract PB1169, ISTH 2020 Congress.

14.

Inbal A. Clin Invest (Lond.) 2015;5(2):137-143.

15.

Zanon E, Pasca S, Radu C et al. Haemophilia. 2019;25(3):e206-e208.

16.

Brand-Staufer B, Carcao M, Kerlin BA et al. Haemophilia. 2015;21(3):380-385.

17.

European Medicines Agency. Guideline on plasma-derived medicinal products. Available at: https://www.ema.europa.eu/documents/scientific-guideline/guideline plasma-derived-medicinal-products_en.pdf  

18.

Fibrogammin® Summary of Product Characteristics.

19.

Australian Public Assessment Report for catridecacog (rys).